New EU indication for Novartis's Lucentis
This article was originally published in Scrip
Novartis's Lucentis (ranibizumab) has now received EU approval for a fourth indication: choroidal neovascularization (CNV) secondary to pathologic myopia (myopic CNV).
You may also be interested in...
The latest drug development news and highlights from our FDA Performance Tracker.
A couple of trials for two investigational late-stage breast cancer candidates from AstraZeneca have each produced encouraging data for a novel drug class where rivals have previously hit clinical buffers.
A mixed sales bag for the Swiss major in Q3 saw a strong start for Pluvicto dampened by a reverse for Zolgensma, weak growth for Cosentyx and continued sluggishness for Leqvio. Positive data for potential blockbuster iptacopan were another bright spot, as Novartis prioritizes the delivery of high value medicines, and concentrates on the US market.